Literature DB >> 27670233

Lung cancer: Stage III NSCLC - is it time to centralize care?

William J Mackillop1, Christopher M Booth1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27670233     DOI： 10.1038/nrclinonc.2016.160

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer.

Authors:  Jin S Lee; Charles B Scott; Ritsuko Komaki; David S Ettinger; William T Sause
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

Review 2.  The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis.

Authors:  Erik M von Meyenfeldt; Gea A Gooiker; Willem van Gijn; Piet N Post; Cornelis J H van de Velde; Rob A E M Tollenaar; Houke M Klomp; Michel W J M Wouters
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

3.  High procedure volume is strongly associated with improved survival after lung cancer surgery.

Authors:  Margreet Lüchtenborg; Sharma P Riaz; Victoria H Coupland; Eric Lim; Erik Jakobsen; Mark Krasnik; Richard Page; Michael J Lind; Michael D Peake; Henrik Møller
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

4.  Should operations be regionalized? The empirical relation between surgical volume and mortality.

Authors:  H S Luft; J P Bunker; A C Enthoven
Journal:  N Engl J Med       Date:  1979-12-20       Impact factor: 91.245

5.  Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non-Small-Cell Lung Cancer.

Authors:  Elyn H Wang; Charles E Rutter; Christopher D Corso; Roy H Decker; Lynn D Wilson; Anthony W Kim; James B Yu; Henry S Park
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

6.  Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Authors:  Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

7.  Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.

Authors:  Bree R Eaton; Stephanie L Pugh; Jeffrey D Bradley; Greg Masters; Vivek S Kavadi; Samir Narayan; Lucien Nedzi; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Douglas W Johnson; Joanne Meng; Walter J Curran
Journal:  J Natl Cancer Inst       Date:  2016-05-19       Impact factor: 13.506

8.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

Authors: 
Journal:  BMJ       Date:  1995-10-07

9.  Mediation analysis of the relationship between institutional research activity and patient survival.

Authors:  Justine Rochon; Andreas du Bois; Theis Lange
Journal:  BMC Med Res Methodol       Date:  2014-01-22       Impact factor: 4.615
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.